Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023

SELL
$9.17 - $19.29 $116,743 - $245,580
-12,731 Reduced 17.25%
61,075 $675,000
Q1 2023

May 09, 2023

BUY
$12.53 - $21.71 $152,089 - $263,515
12,138 Added 19.68%
73,806 $991,000
Q4 2022

Feb 08, 2023

BUY
$11.61 - $16.11 $82,024 - $113,817
7,065 Added 12.94%
61,668 $762,000
Q3 2022

Nov 04, 2022

BUY
$12.21 - $19.7 $69,804 - $112,624
5,717 Added 11.69%
54,603 $760,000
Q2 2022

Jul 29, 2022

SELL
$11.23 - $19.59 $50,523 - $88,135
-4,499 Reduced 8.43%
48,886 $674,000
Q1 2022

May 05, 2022

SELL
$13.37 - $17.79 $206,700 - $275,033
-15,460 Reduced 22.46%
53,385 $867,000
Q4 2021

Jan 21, 2022

SELL
$14.28 - $19.53 $116,981 - $159,989
-8,192 Reduced 10.63%
68,845 $1.12 Million
Q3 2021

Nov 08, 2021

SELL
$12.99 - $20.47 $31,773 - $50,069
-2,446 Reduced 3.08%
77,037 $1.14 Million
Q2 2021

Aug 04, 2021

BUY
$15.46 - $24.5 $452,622 - $717,286
29,277 Added 58.31%
79,483 $1.59 Million
Q1 2021

May 10, 2021

SELL
$19.33 - $37.75 $1.38 Million - $2.69 Million
-71,235 Reduced 58.66%
50,206 $1.16 Million
Q4 2020

Feb 08, 2021

SELL
$24.48 - $42.47 $1.54 Million - $2.67 Million
-62,772 Reduced 34.08%
121,441 $3 Million
Q3 2020

Nov 09, 2020

BUY
$39.09 - $53.44 $5.56 Million - $7.61 Million
142,310 Added 339.62%
184,213 $7.64 Million
Q2 2020

Aug 05, 2020

BUY
$46.7 - $92.04 $1.03 Million - $2.03 Million
22,043 Added 110.99%
41,903 $2.01 Million
Q1 2020

May 06, 2020

SELL
$48.35 - $118.68 $33,893 - $83,194
-701 Reduced 3.41%
19,860 $1.25 Million
Q4 2019

Jan 29, 2020

BUY
$57.36 - $124.1 $138,065 - $298,708
2,407 Added 13.26%
20,561 $2.55 Million
Q3 2019

Nov 01, 2019

BUY
$58.69 - $80.46 $1.07 Million - $1.46 Million
18,154 New
18,154 $1.2 Million
Q1 2018

May 11, 2018

SELL
$52.72 - $67.25 $1,581 - $2,017
-30 Closed
0 $0
Q3 2017

Nov 07, 2017

BUY
$57.01 - $118.75 $1,710 - $3,562
30
30 $2,000

Others Institutions Holding ICPT

About INTERCEPT PHARMACEUTICALS, INC.


  • Ticker ICPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,127,400
  • Description
  • Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...
More about ICPT
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.